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Infections with parasites of the genus Leishmania lead to a rapid, but transient activation
of natural killer (NK) cells. In mice activation of NK cells requires a toll-like-receptor
9-dependent stimulation of dendritic cells (DC) which is followed by the production of
IL-12. Although NK cells appear to be non-essential for the ultimate control of cutaneous
and visceral leishmaniasis (VL) and can exhibit immunosuppressive functions, they form an
important source of interferon (IFN)-γ, which elicits antileishmanial activity in macrophages
and helps to pave a protective T helper cell response. In contrast, the cytotoxic activity of
NK cells is dispensable, because Leishmania-infected myeloid cells are largely resistant
to NK-mediated lysis. In human cutaneous and VL, the functional importance of NK
cells is suggested by reports that demonstrate (1) a direct activation or inhibition of NK
cells by Leishmania promastigotes, (2) the suppression of NK cell numbers or activity
during chronic, non-healing infections, and (3) the recovery of NK cell activity following
treatment. This review aims to provide an integrated view on the migration, activation,
inhibition, function, and therapeutic modulation of NK cells in experimental and human
leishmaniasis.
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A BRIEF INTRODUCTION INTO NK CELLS AND IMMUNITY
TO LEISHMANIA
Natural killer (NK) cells are known for their ability to directly lyse
host cells that express an altered cell surface phenotype follow-
ing a viral infection, malignant transformation, or stress reaction.
The upregulation of ligands for NK cell-activating receptors (e.g.,
NKG2D) or the downregulation of ligands for NK cell-inhibitory
receptors (e.g., members of the Ly49 family) are relevant stim-
uli for NK cell activation in these cases (Lanier, 2008; Yokoyama,
2008). In addition to their cytotoxic potential NK cells also func-
tion as producers of cytokines such as interferon (IFN)-γ and
tumor necrosis factor (TNF), which contribute to the develop-
ment of type 1 T helper (Th1) cells and activate macrophages
for the expression of antimicrobial killing mechanisms (e.g.,
inducible or type 2 nitric oxide synthase [iNOS, NOS2]) (Bogdan,
2001; Stetson et al., 2003; Laouar et al., 2005; Prajeeth et al., 2011).
During systemic infections NK cells were reported to acquire
the potential to produce IL-10 and operate as negative regula-
tors of immune responses due to a feedback inhibition of IL-12
release by dendritic cells (DC) (Maroof et al., 2008; Perona-
Wright et al., 2009). Finally, in certain settings NK cells might
adopt memory-like adaptive activities (Sun et al., 2009).
Leishmaniasis is caused by protozoan parasites of the genus
Leishmania that are transmitted by the bites of sand flies.
Leishmania parasites exist in two distinct morphological forms:
the extracellular, flagellated form that is inoculated into the
mammalian host organism by the vector; and the intracellular,
aflagellated, or amastigote form, which resides or replicates in
various types of target cells (e.g., granulocytes, macrophages, DC,
fibroblasts) (Bogdan et al., 2000; Rittig and Bogdan, 2000; Sacks
and Noben-Trauth, 2002). Depending on the parasite subgenus
[subgenus Leishmania (L.) vs. Viannia (V.)], species and strain,
the dose of transmitted parasites, the inoculation site and the
quality of the immune response of the infected host, the infection
can remain asymptomatic, or turn into a diverse set of clinical
disease manifestations. These include local cutaneous leishmani-
asis (LCL), diffuse cutaneous leishmaniasis (DCL), disseminated
cutaneous leishmaniasis, mucocutaneous or mucosal leishmani-
asis (MCL) as well as visceral leishmaniasis (VL) (Murray et al.,
2005). The control of all forms of leishmaniasis requires the IL-
12-driven differentiation and recruitment of IFN-γ-producing
T helper cells (Mougneau et al., 2011), the presence of IFN-γ-
activated macrophages capable to kill intracellular amastigotes
(Lykens et al., 2010), and mechanisms that prevent hyperinflam-
mation and mediate resolution of the tissue damage (Peters and
Sacks, 2006). Clinical cure of leishmaniasis does not lead to ster-
ile immunity. There is lifelong persistence of small amounts of
parasites which can be reactivated during phases of immunosup-
pression (Bogdan et al., 2000; Belkaid et al., 2002; Bogdan, 2008,
2012).
Several mouse models are available for studying human LCL.
Both in the subcutaneous (s.c.) footpad and the intradermal
(i.d.) ear-infection model inoculation of small or high numbers
of parasites leads to non-ulcerative or ulcerative dermal lesions,
which in several mouse strains closely reflect the self-healing
skin lesions observed in patients with LCL (Mitchell et al., 1982;
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Belkaid et al., 2000). Mimicking VL inmousemodels is somewhat
more challenging, as the intradermal injection of Leishmania
species known to cause VL in humans (e.g., L. L. donovani, L.
L. infantum/L. L. chagasi) does not routinely lead to parasite vis-
ceralization (Leclercq et al., 1996; Ahmed et al., 2003); even after
i.v. infection of the mice a progressive and sustained increase of
the parasite burden is in most mouse strains only observed in
the spleen, but not in the liver (Kirkpatrick and Farrell, 1984b;
Smelt et al., 1997). Nevertheless, the mouse models for cutaneous
and VL have proven useful for studying the innate and adaptive
immune response to a diverse set of Leishmania species caus-
ing CL (e.g., L. L. major, L. V. braziliensis, L. L. mexicana, L. L.
amazonensis) or VL (see above).
In the following I will review the contribution of NK cells to
the development of protective immunity in cutaneous and VL of
mice and man. For the sake of brevity the names of the parasite
species will be given without the subgenus.
RECRUITMENT AND TISSUE INFILTRATION OF NK CELLS
Twenty-four hours after s.c. infection of C57BL/6 mice with L.
major NK1.1+ CD3− NK cells were found to accumulate at the
inoculation site following the prior infiltration of neutrophils.
The immigration of NK cells was associated with an upregula-
tion of the NK cell-activating chemokine IFN-γ-inducible protein
(IP-10 or CXCL9) (Muller et al., 2001). Confocal steady-state and
intravital two-photon real-time fluorescent imaging revealed that
intradermal L. major infection caused the recruitment of NK cells
(CD49b+, MECA-79-negative) from the blood to the draining
lymph node, thereby leading to a 10-fold increase of the absolute
number and a five-fold increase of the percentage of NK cells in
lymph nodes within 24 h (Bajenoff et al., 2006). A similar sequen-
tial infiltration of the skin and the regional lymph node with
neutrophils followed by NK cells (CD49b+) and macrophages
was also observed in BALB/c mice after i.d. infection with L.
infantum chagasi (Thalhofer et al., 2011).
In mouse VL elicited by i.v. infections with L. donovani, NK
cells (CD3−CD49b+NKp46+MHC class II−) were located (1)
in the red pulp and marginal zone of the spleen, where they
increased three-fold from day 0 to day 28; and (2) within the gran-
uloma (ca. 75%) and the parenchyma (ca. 25%) of the liver, in
which the number of NK cells rose by ca. 30% during the first
four weeks of infection (Maroof et al., 2008). Likewise, after i.v.
infections with L. infantumNK cells were readily detectable in the
spleen (Schleicher et al., 2007).
In human leishmaniasis NK cells were detected in lesions of
patients with LCL, DCL, ML, or VL (Salaiza Suazo et al., 1999;
Seixas Duarte et al., 2008; Tuon et al., 2008; Pereira et al., 2009).
However, the findings have to be judged with care as the immuno-
histological analyses were frequently carried out with antibodies
against CD57, a marker that is not selective for NK cells.
ACTIVATION OF NK CELLS
For obvious reasons the kinetics and molecular mechanisms of
NK cell activation and deactivation have been best studied in the
mouse models of CL and VL. NK cell activation results from the
interaction with other cell-types, the stimulation by cytokines,
and from the exposure to certain parasite factors. In cutaneous
L. major infections of self-healing mouse strains, NK cell cyto-
toxic activity and IFN-γ production became readily detectable
in the draining lymph node at day 1 of infection (Scharton
and Scott, 1993; Bajenoff et al., 2006; Liese et al., 2007). The
activation required (1) IL-2 released by antigen-primed CD4+
T cells (Scharton and Scott, 1993; Bihl et al., 2010), (2) IL-12
(Laskay et al., 1995; Scharton-Kersten et al., 1995), which was
expressed by myeloid DC in a TLR9-dependent manner (Liese
et al., 2007), (3) IFN-α/β (expressed by macrophages) and IFN-
α/β-induced iNOS (generated by macrophages and NK cells)
(Diefenbach et al., 1998, 1999), (4) the receptor tyrosine kinase
Tyk2 (Diefenbach et al., 1999; Schleicher et al., 2004) and (5) the
transcription factor IRF-2 (Lohoff et al., 2000). In the absence of
Tyk2 kinase NK cell activity could be partially restored by treat-
ment with IFN-α/β, but not by exogenous IL-12 (Schleicher et al.,
2004).
The activation of NK cells was equally rapid in C57BL/6 mice
infected i.v. with L. infantum. IFN-γ-expressing NK cells and NK
cell cytotoxic activity were detectable in the spleen as early as
12 h after infection. This early splenic NK cell response was abol-
ished by the depletion of CD11c+ myeloid DC, by a deficiency
of the TLR9 receptor, by the deletion of the IL-12p35 subunit
or by the treatment of the mice with an anti-IL-2 receptor anti-
body (Schleicher et al., 2007) (S. Haeberlein, U. Schleicher, and
C. Bogdan, unpublished observations). In contrast, in IL-18−/−
mice the activation of splenic NK cells was only reduced by 50%
(Haeberlein et al., 2010) and in IFN-α/β-receptor−/− mice both
the production of IFN-γ and the cytolytic activity of NK cells
remained largely intact (Schleicher et al., 2007). A lack of IL-15
did not impair the activation of the residual NK cell population
at all (Haeberlein et al., 2010). The NK cell-activating effect of IL-
18 in vivo was not due to an improved IL-12-responsiveness, but
resulted from an up-regulation of Fas-ligand on the NK cell sur-
face (Haeberlein et al., 2010). Whereas splenic CD11c+ myeloid
DC were responsible for the early IL-12 release (Schleicher et al.,
2007), the cellular source of IL-18 has not yet been identified
(Figure 1). An early (day 1 and day 3) IFN-γ response was also
seen in BALB/c mice infected i.v. with L. donovani, but not in
C.B-17 scid mice lacking T and B lymphocytes, which supports
the role of T cell-derived IL-2 in NK cell activation (see above)
and argues against a direct activation of mouse NK cells by this
parasite species (Kaye and Bancroft, 1992; Engwerda et al., 1996).
IL-12p40+ DC were readily observed in the white pulp of the
spleen at day 1 after infection of BALB/c mice with L. donovani
(Gorak et al., 1998).
In the mouse models of cutaneous and VL the only par-
asite factor that has been identified to date to be indirectly
involved in the activation of NK cells is Leishmania DNA.
Genomic, but not mitochondrial (kinetoplast) DNA of L. major,
L. infantum, or L. braziliensis promastigotes activated myeloid
and plasmacytoid DC for the production of IL-12 and IFN-α/β,
respectively, in a strictly TLR9-dependent manner (Liese et al.,
2007; Schleicher et al., 2007) (Figure 1). The genomic DNA of
Leishmania completely mimicked the activity of total (live or
dead) parasites. Importantly, no evidence was obtained for a
direct activation of mouse splenic NK cells by Leishmania DNA
or intact promastigotes, which is in line with the absence of
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FIGURE 1 | Current of view of the activation and function of
NK cells in experimental visceral leishmaniasis (i.v. infection of mice
with L. infantum or L. donovani). Leishmania promastigotes are
endocytosed by CD11c+ myeloid DC, which subsequently produce the
NK cell-activating cytokine IL-12 in a TLR 9-dependent manner (Schleicher
et al., 2007). In addition to IL-12 the cytokine IL-2 (in analogy to previous
findings in mouse L. major infections (Scharton and Scott, 1993; Bihl et al.,
2010) presumably derived from CD4+ T lymphocytes) is also essential
for the early activation of NK cells, whereas IL-18 (the source of which is
currently unknown) only plays a contributory role and IL-15 is completely
dispensable in this process (Haeberlein et al., 2010) (S. Haeberlein, U.
Schleicher, and C. Bogdan, unpublished observations). Exposure
of plasmacytoid dendritic cells (pDC) to Leishmania promastigotes
leads to a massive release of type I interferons (IFN-α/β), which, however, is
of minor relevance for the activation of splenic NK cells (Schleicher et al.,
2007), unlike to the cutaneous infection model (Diefenbach et al., 1998).
Infected myeloid cells such as macrophages (M) are resistant to NK cell
lysis in vitro and in vivo. Instead, activated NK cells secrete IFN-γ, which
activates M for the killing of intracellular amastigotes, a process that
requires TNF and iNOS expressed by the M (Prajeeth et al., 2011). NK
cell-derived IL-10 might antagonize this process later during infection (Maroof
et al., 2008).
TLR9 on highly purified mouse splenic NK cells (Schleicher et al.,
2007).
In the human system various products of Leishmania have
been described to directly or indirectly activate NK cells. Purified
L. major lipophosphoglycan (LPG), the major surface glycophos-
pholipid of promastigotes, was shown to bind to TLR2, to
enhance the TLR2 protein expression on themembrane of human
NK cells, and to trigger their production of TNF and IFN-γ
(Becker et al., 2003). This finding is in accordance with the low
levels of TLR2 mRNA previously detected in primary human NK
cells (Hornung et al., 2002). In another study, however, live pro-
mastigotes of L. aethiopica, L. mexicana, or L. donovani directly
activated NK cells from naive human donors in the absence of
myeloid cells and IL-12 for the production of IFN-γ even when
LPG- or proteophosphoglycan-deficient parasite mutants were
used, a finding which questions the stimulatory role of LPG
(Nylen et al., 2003). In a later publication by the same group
two strains of L. major behaved differently and failed to trigger
NK cell IFN-γ release (Lieke et al., 2008). When peripheral blood
mononuclear cells (PBMNC) from healthy donors were exposed
to the L. braziliensis homolog of the eukaryotic ribosomal elon-
gation and initiation factor 4α (LeIF) (Borges et al., 2001), to
the 36 kDa L. major homolog of receptors for activated C-kinase
(LACK) (Maasho et al., 2000), or to the cysteine proteinase P-2
of L. aetiopica amastigotes (Nylen et al., 2004), NK cells showed
strong expression of IFN-γ. In all these cases, however, the acti-
vation of NK cells was dependent on the presence of adherent
myeloid cells (producing the NK cell-stimulating cytokines IL-
12 and IL-18), which argues against a direct effect of leishmanial
products on NK cells. PBMNC from Ethiopian patients with
active LCL also reacted to recombinant LACK antigen and to
the P-2 and P-8 antigens of L. aethiopica amastigotes, with NK
cells showing the most prominent proliferative response (Maasho
et al., 2001, 2003).
Together, these data show that the activation of NK cells in
mouse and human leishmaniasis primarily occurs via an inter-
action with myeloid cells and requires the production of NK
cell-stimulatory cytokines (Table 1).
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Table 1 | Activation, suppression and function of NK cells in mouse and human cutaneous and visceral leishmaniasis (for references see text).
Parameter Mouse Human
Activation of NK cells Host components:
TLR9-positive myeloid DC
IL-2 (T cell-derived; essential)
IL-12 (DC-derived; essential)
IL-15 (dispensable)
IL-18 (contributory)
IFN-α/β (CL: essential; VL: weakly contributory)
iNOS/NO (CL: required)
Tyk2 kinase (CL: essential)
Interferon regulatory factor-2
Parasite components:
genomic DNA
Host components:
TLR2-positive NK cells
adherent myeloid cells
Parasite components:
live promastigotes (L. aethiopica, L. mexicana
[wildtype, LPG- or PPG-mutant], L. donovani)
L. major LPG (?)
L. braziliensis LeIF-protein
L. major LACK-protein
L. aethiopica P2-protein
Suppression of NK cells inhibition of CXCL9 release by L. major
poor induction of IL-12 by Leishmania
promastigotes
suppression of IFN-γ release by TGF-β
IL-10 (?)
live L. major promastigotes (wildtype or gp63-mutant)
L. major gp63 (?)
Function of NK cells CL:
disease-ameliorating
improved Th1 development
IFN-γ-mediated macrophage activation for
killing of intracellular Leishmania
VL:
disease-ameliorating or
disease-aggravating (via IL-10 release)
CL and VL:
protective effect (inverse correlation between NK cell
numbers and disease)
killing of extracellular L. major or L. amazonensis
promastigotes
CL, cutaneous leishmaniasis; LPG, lipophosphoglycan; PPG, proteophosphoglycan; VL, visceral leishmaniasis.
SUPPRESSION OF NK CELL ACTIVITY
In experimental CL (L. major) and VL (L. infantum, L. dono-
vani) the activation of NK cells in the draining lymph node
and the spleen is characterized by a strong initial peak (12–
48 h post-infection) and a steady decline thereafter (Kirkpatrick
and Farrell, 1984a,b; Scharton and Scott, 1993; Schleicher et al.,
2007); in experimental VL the NK cell activity might even fall
below the levels in uninfected control mice (Kirkpatrick and
Farrell, 1984a,b). Several factors might account for this tran-
sient NK cell activation and subsequent suppression. First, L.
major is able to inhibit the IFN-γ-induced expression of the NK
cell-attracting chemokine IP-10 (CXCL9) by neutrophils (van
Zandbergen et al., 2002), which might prevent an ongoing influx
of NK cells from the blood. Second, the NK cell response might
be curtailed by cytokines that are known to inhibit NK cell pro-
liferation and/or activity. In non-healing BALB/c mice, which
show a considerably weaker NK cell activity after L. major infec-
tion than self-healing mouse strains (Scharton and Scott, 1993;
Laskay et al., 1995; Mattner et al., 2004), expression of a dominant
negative mutant of the transforming growth factor-β receptor
II (dnTGF-βRII) led to a persistently increased number of NK
cells and a higher percentage of IFN-γ+ NK cells in the drain-
ing lymph nodes as compared to control BALB/c mice (Laouar
et al., 2005). This finding is in line with the previous observa-
tion that TGF-β is much more abundant in the skin lesions of
L. major-infected BALB/c compared to C57BL/6 mice (Stenger
et al., 1994) and that the IFN-γ production of BALB/c lymph
node cells at day 2 after L. major infection is 20-fold increased
in the presence of anti-TGF-β1/β2/β3 antibodies in the culture
(Scharton-Kersten et al., 1995). The IFN-γ expression of human
NK cells is also susceptible to suppression by TGF-β (Yu et al.,
2006), although this has not yet been formally demonstrated in
patients with leishmaniasis. Another candidate for the limitation
of the NK cell response following Leishmania infections is the
cytokine IL-10, which is generated bymacrophages, Th1 cells, and
regulatory T cells (Assenmacher et al., 1994; Kane and Mosser,
2001; Belkaid et al., 2002; Anderson et al., 2007; Nagase et al.,
2007), but also by activated mouse and human NK cells (includ-
ing those from patients with LCL) (Akuffo et al., 1999; Maasho
et al., 2003; Maroof et al., 2008). It should be emphasized that
both NK cell-inhibitory andNK cell-stimulatory effects have been
described for IL-10 in various settings (e.g., Shibata et al., 1998;
Tu et al., 2008). The role of IL-10 for NK cell activation ver-
sus suppression in leishmaniasis remains to be defined. Third,
certain Leishmania species (e.g., L. tropica, L. mexicana, L. ama-
zonensis, L. donovani), notably in their amastigote stage, are poor
inducers of IL-12 production by DC, which might account for
the limited NK cell response during prolonged infections in vivo
(Bennett et al., 2001; McDowell et al., 2002; Maroof and Kaye,
2008; Sanabria et al., 2008). Fourth, the activation or survival of
NK cells might be negatively regulated by the parasite itself. In
this respect, intact L. major promastigotes (Lieke et al., 2008),
crude antigenic fractions of L. major (Turhan et al., 1997) as well
as the 63 kDa glycoprotein of L. major (gp63, leishmanolysin,
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or Leishmania major surface protease) (Lieke et al., 2008) were
shown to inhibit the IFN-γ production, proliferation and/or cyto-
toxicity of human NK cells. gp63 was shown to bind to purified
human NK cells, to inhibit their IL-2-driven proliferation, and
to downregulate various NK cell receptors (CD16, CD56, NKp30,
NKp44) (Lieke et al., 2008). A dominant NK cell-regulatory func-
tion of gp63, however, was questioned by the observation that in
a less artificial situation, i.e., in a culture of total PBMNC, the
NK cell-suppressive effect of L. major parasites was also observed
with gp63-deficient mutants (Lieke et al., 2008). A recently
observed final facet of the interaction between human NK cells
and Leishmania might be the induction of non-apoptotic NK cell
death immediately after their contact with promastigote parasites
(Lieke et al., 2011).
Together, these data argue for both direct and indirect modes
of NK cell suppression during mouse and human L. major infec-
tions (Table 1).
FUNCTION OF NK CELLS IN MOUSE AND HUMAN
LEISHMANIASIS
PHENOTYPIC ANALYSES
In mouse CL it is thought that NK cells contribute to a protec-
tive immune response against Leishmania parasites. This view has
been based on the increased tissue parasite load and/or the aggra-
vated course of infection in transiently NK cell-depleted L. major-
or L. amazonensis-infected mice and on the disease-amelioriating
effect of the in vivo activation or the transfer of NK cells in these
models (Laskay et al., 1993; Scharton and Scott, 1993; Laurenti
et al., 1999; Sanabria et al., 2008). There are two caveats about
the antibody-based NK cell depletion experiments (Laskay et al.,
1993; Scharton and Scott, 1993): first, the antibody application
was limited to a time period of 2–7 days prior to and 14 days
after infection, which offers an explanation that the ultimate out-
come of the infection was indistinguishable in the treatment and
control group (Laskay et al., 1993). Second, the antibodies used
(anti-asialo-GM1; anti-NK1.1) not only target CD3−NK1.1+ NK
cells, but also CD3+NK1.1+ natural killer T (NKT) as well as
CD8+ T cells that can acquire the expression of NK1.1 or asialo-
GM1 (Assarsson et al., 2000; Slifka et al., 2000). NKT cells were
later shown to participate in the control of L. major in the skin
lesions (Mattner et al., 2006). As an alternative approach, a T-
and NK-cell-deficient transgenic C57BL/6 ×CBA/J mouse strain
expressing high copy numbers of the human CD3ε gene (tgε26)
was used, as neonatal transplantation of wild-type bone marrow
cells into these mice was found to result in normal amounts of T
cells, but a massively reduced number of NK cells. When recon-
stituted tgε26 mice (NK−T+) were infected with L. major, the
parasite burden in the skin lesion and the clinical course of infec-
tion was comparable to the respective NK cell-proficient control
mice (Satoskar et al., 1999). This result contrasts with obser-
vations made with the above-mentioned dnTGF-βRII BALB/c
mice, in which the enhanced number and IFN-γ expression of
NK cells led to the control of L. major in otherwise non-healing
BALB/c mice (Laouar et al., 2005). With the exception of the
activating NK cell receptor Ly49H, which turned out to be dis-
pensable for the course of L. major infection in C57BL/6 mice
(Fodil-Cornu et al., 2008), there is no information to date on
the possible involvement of other NK cell receptors during the
immune response to Leishmania parasites.
In experimental VL the first evidence for a protective role of
NK cells was obtained by the analysis of beige (bg/bg) mice, which
lack the gene for the lysosomal trafficking regulator (LYST or
Beige gene). This genetic defect leads to abnormally enlarged lyso-
somes and lysosome-related organelles, to degranulation defects
and to a defect of NK cell cytotoxicity (Roder and Duwe, 1979),
whereas the IFN-γ production of NK cells apparently remains
intact (Kawase et al., 1983; Mohan et al., 1997). Although the
Beige mutation is not specific for NK cells [reference (Wilson
et al., 2008) and references therein], the failure of C57BL6J bg/bg
mice to control L. donovani amastigotes in the spleen (Kirkpatrick
and Farrell, 1982) could be corrected by the transfer of syn-
geneic NK cells derived from a IL-2-dependent NK cell line
(Kirkpatrick et al., 1985). The finding that the therapeutic effect
of recombinant IL-12 in L. donovani-infected mice was prevented
in anti-asialo-GM1-treated mice is likewise compatible with a
beneficial role of NK cells (Murray and Hariprashad, 1995), but
might also result from the activity of NKT cells (Amprey et al.,
2004). Independent of a possible protective effect of NK cells in
wild-type mice, additional studies in cytokine- or amphotericin
B-treated nude mice (B- and T-cell-deficient) and euthymic bg/bg
mice (defective NK cells) as well as in the hamster model of VL
revealed that NK cells are neither sufficient nor essential to con-
trol L. donovani (Murray et al., 1995; Sartori et al., 1999; Murray,
2005). In addition, one study even demonstrated that activated,
IL-10-expressing NK cells antagonized the control of L. dono-
vani in the spleen and in the liver as shown by cell depletion and
adoptive transfer experiments (Maroof et al., 2008) (Figure 1).
Several findings indicate a protective role of NK cells in human
leishmaniasis. These include (1) the enhanced proliferation of
NK cells within PBMNC from cured or control individuals resid-
ing in an endemic area as compared to patients with active LCL
lesions after in vitro stimulation with the respective parasite anti-
gen (L. aethiopica) (Maasho et al., 1998); (2) the influx of NK cells
into lesions of DCL patients who showed a response to treatment
(Salaiza Suazo et al., 1999; Pereira et al., 2009); (3) the suppres-
sion of cytolytic NK cell activity in patients with active VL, which
could be restored in vitro by stimulation with IL-2 (Manna et al.,
1993); and (4) the normalization of NK cell numbers following
successful chemotherapy of VL (Cenini et al., 1993).
MECHANISTIC ANALYSES
Despite the caveats discussed above there is no doubt that NK
cells are rapidly activated during CL and VL. The phenotypic
observations that support a host-protective function of NK cells
in leishmaniasis raise the question of possible underlying mech-
anisms. There is evidence for several scenarios. First, considering
the documented in vitro interaction between activated humanNK
cells and L. major promastigotes (Lieke et al., 2008, 2011) and the
susceptibility of L. major to granulysin (Stenger et al., 1998), a
major cytotoxic effector molecule of human NK cells and CD8+
T cells, direct lysis of extracellular parasites is feasible. Indeed, two
reports showed killing of L. major or L. amazonensis promastig-
otes by (IL-2 activated) humanNK cells (Aranha et al., 2005; Lieke
et al., 2011), whereas in two other studies (IL-2 activated) mouse
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splenic NK cells and/or human peripheral blood NK cells were
unable to lyse extracellular L. donovani promastigotes (Manna
et al., 2010) or amastigotes (Saha et al., 1999). The relevance of
these findings for the control of infection remains unclear as a
direct encounter between NK cells and free Leishmania parasites
has not yet been demonstrated in vivo (Moreno et al., 2010).
A second mechanism for the protective function of NK cells
could be the lysis of Leishmania-infected host cells. This possi-
bility appears principally realistic, because macrophages, DC and
NK cells have been detected in close proximity to each other in
the medulla and paracortex of L. major-infected lymph nodes
(Bajenoff et al., 2006) and in the marginal zone and periarteriolar
lymphocytic sheaths of L. donovani-infected spleens (Gorak et al.,
1998; Lang et al., 2000; Maroof et al., 2008). Two in vitro studies
claimed lysis of BALB/c macrophages infected with L. major or
L. amazonensis promastigotes by IL-2-activated splenic killer cells
(LAK) (Resnick et al., 1988; Aranha et al., 2005). The meaning-
fulness of the obtained results, however, is questionable as (1) the
LAK preparations were either phenotypically not characterized
(Resnick et al., 1988) or contained ca. 15% NKT and/or CD8+
T cells (Aranha et al., 2005), which are known to lyse and activate
Leishmania-infected myleoid cells (Stefani et al., 1994; Campos-
Martin et al., 2006); (2) extremely high LAK-macrophage ratios
(≥10:1) and Leishmania-macrophage ratios (≥40:1) were used
(Resnick et al., 1988); and (3) the analysis lacked a quantification
and the use of uninfected control target cells (Aranha et al., 2005).
Our recent detailed analysis using mouse bone marrow-derived
resting, inflammatory peritoneal exudate macrophages or bone
marrow-derived DC revealed that neither L. major nor L. infan-
tum promastigotes or amastigotes modulated the expression of
activating or inhibitory NK cell ligands. Accordingly, myeloid cells
infected with Leishmania parasites did not become targets for the
cytolytic activity of activated NK cells in vitro and in vivo (Prajeeth
et al., 2011) (Figure 1). Likewise, J774G8-1 tumor macrophage
cells infected with L. mexicana were not killed when exposed to
normal spleen cells from mouse strains with high or low NK cell
activity (Merino and Cruz, 1984). Immature human DC infected
with L. infantum showed an upregulation of HLA-E, a ligand for
the NK cell inhibitory receptor CD94/NKG2A, which made them
also resistant to NK cell-mediated cytotoxicity (Campos-Martin
et al., 2006). As expected from these in vitro findings, the clinical
course of L. major infection in C57BL/6J bg/bg mice was indis-
tinguishable from the respective control mice (Kirkpatrick and
Farrell, 1982). Why the beige mutation caused a lack of parasite
control in the spleen of L. donovani-infected mice (Kirkpatrick
and Farrell, 1982) despite the resistance of infected myeloid cells
to NK cell-mediated lysis, is mechanistically not yet understood.
It is possible that the phenotype results from the defect of NK cell
cytotoxicity against non-myeloid target cells or from a defect of
other cytotoxic cells (e.g., CD8+ T cells). In this context it is worth
noting that intracellular parasite antigens were detected within
human peripheral blood γ/δ T cell blasts upon exposure to L.
donovani amastigotes and that these cells were lysed by human
NK cells (Saha et al., 1999).
A third mechanism by which NK cells might convey protec-
tion in leishmaniasis is via their production of IFN-γ. Indeed,
NK cells that were activated by IL-12 plus IL-18, stimu-
lated macrophages for the killing of intracellular L. infantum
amastigotes in an IFN-γ-, TNF-, and iNOS-dependent, but cell
contact-independent manner. The source of the TNF was the
macrophages rather than the NK cells (Prajeeth et al., 2011).
There is also strong evidence that NK cell-derived IFN-γ paves the
development of Th1 cells during mouse L. major infections, espe-
cially if the TGF-β-mediated suppression of this process is blocked
(Laouar et al., 2005). On the other hand, it is important to bear
in mind that (1) NK cells as the only source of IFN-γ are insuffi-
cient to control a L. major infection (Wakil et al., 1998); (2) Th1
cells will also develop in the absence of NK cell-derived IFN-γ
(Wakil et al., 1998; Satoskar et al., 1999) and that (3) vaccine-
induced protective immunity against Leishmania parasites can
also occur after depletion of NK cells, although the vaccination
efficacy might be somewhat reduced (Streit et al., 2001; Remer
et al., 2010).
CONCLUSION AND OUTLOOK
The results obtained with experimental mouse models allow the
conclusion that NK cells are non-essential for the resolution of
CL. The same presumably holds also true for mouse VL, although
definitive studies with NK cell-selective reagents or transgenic
mice have not yet been performed. Ongoing studies in our group
are addressing this issue with genetic models that allow consti-
tutive versus inducible NK cell depletion. Independent of the
question whether NK cells are essential or dispensable for the
control of Leishmania parasites, there is convincing evidence for
a protective function of NK cells in mouse CL, which is mainly
based on the IFN-γ-mediated activation of macrophages and
development of Th1 cells. In experimental VL it is possible that
NK cells also exert immunosuppressive and disease-aggravating
effects due to the production of IL-10, whereas the limited stud-
ies in patients with VL rather point to a host-protective role
of NK cells.
Considering that NK cells are a potent source of IFN-γ, vari-
ous approaches have been tested in experimental CL to stimulate
NK cell activity in order to improve the course of infection or
to enhance the protection conveyed by vaccines. Beneficial effects
that were associated with the activation of NK cells were previ-
ously obtained in L. major- or L. amazonensis-infected mice by
prior treatment with the TLR3-agonist polyinosinic:polycytidylic
acid (poly I:C) (Laskay et al., 1993), by vaccination with live par-
asites containing the TLR9 agonist CpG 1826 (Laabs et al., 2009),
by injection of an IL-12-expression plasmid (Sakai et al., 2000)
or an IL-12-expressing adenovirus (Gabaglia et al., 1999), or by
feeding an immunostimulatory fungal β-glucan (Yatawara et al.,
2009). Whether the transfer of allogeneic NK cells, which yielded
promising results in L. donovani-infected mice (Manna et al.,
2010), is a clinically reasonable approach for the treatment of
chronic Leishmania infections in humans, awaits further analysis.
Attractive future strategies for NK cell-based immunotherapies
include the application of reagents that specifically stimulate NK
cells (e.g., antibodies crosslinking activating NK cell-receptors).
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